Skip to content

Trial Summary

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.



ACTRN/NCT /ethics:


Scientific title:

A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer

Sponsor / Cooperative group:

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Trial & Patient Characteristics

Cancer TypeOvarian Cancer
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2020-10-26
Anticipated End Date2024-08-01

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead/Kate Penda
Phone08 8359 2565
Principal InvestigatorDr Meena Okera
Recruitment StatusRecruiting